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Abstract
Psychotherapy research aims to investigate predictors and moderators of treatment outcome,
but there are few consistent findings. This study aimed to investigate cytokines in patients
undergoing treatment for anxiety disorders and whether the level of cytokines moderated
the treatment outcome. Thirty-seven patients with comorbid and treatment-resistant anxiety
disorders were investigated using multilevel modelling. Serum cytokine levels were measured
three times: pretreatment, in the middle of treatment, and at the end of treatment. Anxiety and
metacognitions were measured weekly throughout treatment by self-report. The levels of
monocyte chemoattractant protein-1, tumour necrosis factor-alpha, and interleukin-1 receptor
antagonist did not change during therapy or were not related to the level of anxiety.
Metacognitive beliefs predicted anxiety, but the relationship between metacognitions and anxi-
ety was not moderated by cytokines. Limitations of the study include that the patients were not
fasting at blood sampling, and we did not assess body mass index, which may affect cytokine
levels. The lack of significance for cytokines as a predictor or moderator may be due to a lack of
power for testingmoderation hypotheses, a problem associated withmany psychotherapy stud-
ies. Cytokines did not predict the outcome in the treatment of comorbid anxiety disorders in our
sample. Furthermore, cytokines did not moderate the relationship betweenmetacognitions and
anxiety.
Significant outcomes
• Cytokines did not predict the outcome in the treatment of anxiety disorders
• Level of cytokines did not moderate the relationship between metacognitions and anxiety.
Limitations
• Patients were not fasting at blood sampling.
• Body mass index was not assessed.
• Sample size indicates reduced power to detect significant moderators.
Introduction
Anxiety disorders are among themost commonmental disorders (Kessler et al., 2005), and there
is evidence that psychological treatments are effective (Hans &Hiller, 2013). The disorders often
co-occur (Kessler et al., 2012) with substance use disorders, especially alcohol, and researchers
have, therefore, started to investigate processes that are common across different anxiety dis-
orders, so-called transdiagnostic processes (Harvey et al., 2004). Irrespective of whether anxiety
disorders are studied separately or as a syndrome, there is no single treatment effective for every-
one. Thus, there is an interest to investigate what works for whom, enabling a form of more
personalised medicine (Insel, 2009). Knowledge about predictors and moderators of treatment
outcome are thus needed (Kraemer et al., 2002). Predictor variables, clinical or biological, pro-
vide information on the associated dependent variable. Moderator variables are identified when
the relationship between two variables depends on a third variable.
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In psychotherapy research, metacognitions (Wells, 2009) have
been found to be an important time-varying process predictor
called a within-person effect (Johnson et al., 2018). Typically, in
psychotherapy research, individuals are compared with other indi-
viduals, called a between-person effect (Molenaar, 2004). However,
a within-person effect isolates how a patient changes over the
course of therapy related to their usual level. Thus, in the study
by Johnson et al. (2018), the following clinical implication could
be drawn based on a within-person finding: If a clinician targets
metacognition in therapy, reduction in anxiety will likely follow.
According to metacognitive therapy (MCT) (Wells, 2009), the
use of specific strategies to regulate emotions is dependent on meta-
cognitions. Metacognition was originally defined as knowledge or
beliefs about thinking and strategies used to regulate and control
thinking processes (Flavell, 1979). Metacognitions are crucial for
the development and maintenance of psychological disorders
(Wells, 2009). In therapy, two types of metacognitive beliefs are tar-
geted, positive and negative. Positivemetacognitive beliefs are beliefs
about the usefulness of worry, ruminations, and threat monitoring
(e.g. ‘If I worry, I will be prepared’, ‘If I ruminate, I will find a sol-
ution’). Negativemetacognitive beliefs concern the uncontrollability
of thoughts and their danger (e.g. ‘I cannot control my thoughts’,
‘Worry can damage mymind’). In therapy, the therapist has to iden-
tify the specific strategies to regulate emotions (e.g. worry and rumi-
nation) and the metacognitive beliefs that give rise to the use of this
strategy and challenge this. Previous studies from our group have
shown that metacognition, in general, and positive metacognitions,
specifically, predict anxiety on a within-person level (Hoffart et al.,
2018; Johnson et al., 2018).
It is an open question whether the within-person effect of meta-
cognitions on outcome ismoderated by specific characteristic. Thus,
an important research goal is to find characteristics that explain vari-
ability in within-person relationships between meta-cognitions and
subsequent symptoms. A recent systematic review stated that many
studies found associations between psychological treatment and
inflammation (Moraes et al., 2018). Further, it was mentioned that
little is known about the impacts of psychoneuroimmunological
interventions and the effects on disease progression (Moraes et al.,
2018). Aiming to fill this gap in the literature, the current study
explores the potential moderating role of cytokines on psychological
treatment in anxiety patients.
Findings regarding predictors of the outcome in anxiety disorder
treatment are inconclusive. For example, some studies find associa-
tions between the degree of comorbidity or personality problems
and the outcome (Bohart &Wade, 2013; Goddard et al., 2015), while
other studies do not (Hoffart et al., 2015; Johnson & Hoffart, 2019).
One reason for the lack of consistent findings may be that the predic-
tors and moderators of treatment outcome investigated have been
psychological constructs (Schneider et al., 2015), and these psycho-
logical constructs are often poorly defined, limiting construct validity
(Fried, 2017). Anxiety disorders should be understood in a biopsycho-
social framework (Engel, 1977). It is, therefore, of clinical interest to
investigate possible biological predictors of their outcome. Such bio-
logical predictors could be, for example, the immunologicalmolecules
cytokines. Cytokines constitute a group of smallmessengermolecules,
which commonly are divided into two families, pro- and anti-
inflammatory cytokines. The research efforts for investigating the
association between cytokines and anxiety disorders are increasing
(Vogelzangs et al., 2013).
Inflammatory cytokines may be associated with behavioural
change in many ways. They may alter the metabolism of neurotrans-
mitters such as serotonin, dopamine, and glutamate (Moron et al.,
2003) and also influence the hypothalamic–pituitary–adrenal axis
through their actions towards the release of corticotrophin-releasing
hormone, adrenocorticotropic hormone, and cortisol (Raison et al.,
2010). Pro-inflammatory cytokines, such as interleukin-1 (IL-1),
interleukin-6 (IL-6), interferon-gamma (IFN-γ), monocyte chemoat-
tractant protein-1 (MCP-1), and tumour necrosis factor-alpha
(TNF-α), enhance the immune response to help speed the elimination
of pathogens and the resolution of the inflammatory challenge
(Kronfol & Remick, 2000; Dalgard et al., 2017). Also, levels of
anti-inflammatory cytokines have been reported to be altered in gen-
eralised anxiety disorders when compared to healthy controls, con-
tributing to an altered cytokine balance (Hou et al., 2017).
Therefore, the anti-inflammatory cytokine interleukin-1 receptor
antagonist (IL-1RA) was also assessed in the current study.
Elevated levels of cytokines have been found for panic disorder
and post-traumatic stress disorder (PSTD) (Hoge et al., 2009) and also
for anxiety disorders in general (Vogelzangs et al. 2013). Furthermore,
an association between inflammatory dysregulation and anxiety – for
example, for TNF-α – has been reported (Renna et al., 2018).
However, the association between TNF-α and anxiety disorders is
not found in a recent paper (Glaus et al., 2018).
Thus, the evidence concerning specific cytokines and the rela-
tionship with anxiety disorders is inconclusive. To our knowledge,
no studies have investigated cytokines in relation to treatment out-
come in anxiety disorders.
Aims of the study
In this exploratory study, we firstly wanted to investigate if the pre-
treatment level of anxiety correlated with the levels of some
selected cytokines. Then we examined how cytokines developed
over the course of therapy for comorbid anxiety disorders and
whether the mean level of cytokines predicted anxiety. Thirdly,
we investigated whether the mean level of cytokines moderated
the within- and between-person relationship between a therapy
process (meta-cognitions) and anxiety over the course of therapy.
Materials and method
Participants
The patients were referred to the Department of Anxiety Disorder
at Modum Bad because they had not benefited sufficiently from
outpatient treatment and were undergoing an 8-week inpatient
treatment program for treatment resistance. Patients enrolled at
the Department of Anxiety Disorders have, on average, 3.7 diag-
noses at intake (Johnson et al., 2017). Thus, the terms comorbid
anxiety and treatment-resistant anxiety disorders are used. The
study included 37 patients who were undergoing treatment. The
average duration of anxiety disorder problem was 16 years, and
85% of the patients were either disabled, out of work, or on sick
leave when entering treatment (Johnson et al., 2017). Primary diag-
noses treated at the department are PTSD, social phobia, panic dis-
order with and without agoraphobia, generalised anxiety disorder
(GAD), and specific phobia. The term comorbid anxiety disorders
refers to patients which is homogeneous in terms of having anxiety
disorders and possible common processes underlying them but
heterogeneous in terms of the composition of anxiety disorders.
Thus, the patients represent a typical clinical sample. Some patients
used medications which are known to have immunomodulatory
properties. There were 10 patients who used Paracetamol, five
patients used Paracetamol and Ibuprofen in combination, three
patients used Ibuprofen, three patients used Escitalopram, one
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patient used Diclocil antibiotics, and one patient used Diclofenac.
Since few patients used medications at all, and only five patients
used Paracetamol and Ibuprofen for more than a single-occurring
event, we did not take the use of medication into consideration in
the analyses.
There were 17 male and 20 female patients in the study. The
mean age was 43.6 years (SD= 11.0 years). The following primary
diagnoses were present: 14 patients had PSTD, 7 patients had social
phobia, 5 patients had panic disorder with agoraphobia, 1 patient
had GAD, and 1 had a specific phobia. Nine patients did not have
any specific registered diagnosis, but had either PTSD, SAD, PDA,
or GAD, since that is the inclusion criteria for treatment at the
Department of Anxiety Disorder.
The patients were part of a larger study investigating cytokines
in psychological disorders (Toft et al., 2018). The study was
approved by the Norwegian Regional Ethics Committee prior to
data collection (reference number 2014/2189), and the participants
gave their written consent.
Treatment
At the Department of Anxiety Disorders, MCT and cognitive behav-
ioural therapy (CBT) are administered. TheMCT (N= 15) consists of
a manualised treatment protocol for the generic MCT model (Wells,
2009). The CBT (N= 22) is based on disorder-specific models for
panic disorder (Wells, 1997), social phobia (Clark & Wells, 1995),
and PSTD (Foa et al., 2007). Both treatments have in common that
they are highly structured, are based on establishedmanuals, and have
shown efficacy in the treatment of anxiety disorders. In the current
study, we did not separate between the two treatments; thus, the
results encompass the treatment of anxiety disorders using either
CBT or MCT.
Self-report measures
Anxiety and metacognitions were measured weekly throughout
treatment through self-report. Beck Anxiety Inventory (BAI;
Beck et al., 1988) measures anxiety symptoms the last week with
21 items. The items are rated on a Likert scale from 0 to 3 with
a maximum score of 63. The psychometric properties of the
BAI are satisfactory (e.g. Steer et al., 1993). The Meta-Cognitions
Questionnaire 30 (MCQ-30; Cartwright-Hatton & Wells, 1997)
measures metacognitive beliefs. The items are rated on a 4-point
Likert scale, and the total score varies from 30 to 120. MCQ-30
has been found to have adequate psychometric properties
(Wells & Cartwright-Hatton, 2004).
Serum preparation and cytokine measurements
Peripheral circulating cytokines were measured pretreatment, in
the middle of treatment, and at the end of treatment. The length
of stay, and thus the number of weeks between each blood sample,
varied between the various enrolments due do holiday seasons and
other treatment-related events. Thus, the average amount of time
from baseline to T1 was 4 weeks, and from baseline to T2 was
8 weeks. The blood samples were taken at the local hospital labo-
ratory between 08:00 a.m. and 09:00 a.m. Samples were collected in
Vacuette 8 ml serum tubes, immediately turned upside down 8–10
times, and set to rest between 30 and 60 min, and lastly centrifuged
in a Kubota 2420 swing-out centrifuge at room temperature for
10 min at 1917 g. The separated serum was stored in two 2ml
Nunc tubes in a −80°C freezer until assay.
Before analysis, samples were thawed on ice, vortexed, and spun
down at 14 000× g for 10min at 4°C. Cytokines were measured by
using Bio-Plex xMAP technology (Bio-Rad, Austin, TX, USA) with a
Luminex IS 100 instrument (Bio-Rad, Hercules, CA, USA), powered
using Bio-Plex Manager (version 6.0.1) software. The StatLIA soft-
ware package (version 3.2, Brendan Scientific, Carlsbad, CA, USA),
incorporating a weighted, five-parameter logistic curve-fitting
method, was used to calculate sample cytokine concentrations. We
present data on MCP-1, TNF-α, and IL-1RA because they are within
the detectable range. Inter-assay coefficients of variability (CV) were
6.7% for MCP-1, 7.4% for TNF-α, and 10.2% for IL-1RA, all within
the 21% acceptability limit. All zero valueswere replacedwith the limit
of detection (LOD). At T0, the median level of MCP-1 was 23.29, and
the LODwas 6.48. There were 3 zero values which were replaced with
the LOD. Themedian level in TNF-αwas 0.18, and the LODwas 0.08.
There were 15 zero values which were replaced with the LOD. The
IL-1RA median level was 32.25, and the LOD was 7.87. There were
no zero values. At T1, the MCP-1 median level was 24.24, and the
LOD was 3.56. There was one zero value which was replaced with
the LOD. The TNF-α median level was 0.42, and the LOD was
0.36. There were 13 zero values which were replaced with the
LOD. The IL-1RA median level was 29.65, and the LOD was 8.32.
There were no zero values. At T2, the MCP-1 median level was
23.54, and the LOD was 4.33. There were four zero values replaced
with the LOD. The TNF-α median level was 0.26, and the LOD
was 0.02. There were 15 zero values which were replaced with the
LOD. The IL-1RA median level was 31.95. The LOD was 6.69.
There were no zero values. The cytokine, which was omitted from
the study, is presented together with its median values and the
LODs. At T0, the IL-1β median level was 0.06, and the LOD was
0.03. At T1, the IL-1β median level was 0.08, and the LOD was
0.01. At T2, the IL-1β median level was 0.07, and the LOD was 0.03.
Statistical analysis
The data used in the process outcome analyses were nested in a
two-level structure (weeks nested within patients) thus longi-
tudinal multilevel modelling (MLM) was used for the analysis
(Fitzmaurice et al., 2004; Curran & Bauer, 2011).
MLMmakes use of all available data in the estimation of model
parameters. Thus, a participant with missing data can be included
in the analysis and affect the estimation of model parameters
(Kwok et al., 2008). In this study, the process variable, metacogni-
tion, was disaggregated in both within and between effects accord-
ing to the criteria outlined by Wang and Maxwell (2015), using
person-mean centering. Thus, two variables were entered into
the prediction analysis, a between-patient and a within-patient
effect. Disaggregation is important because the raw score reflects
two sources of variance: how an individual differs from other indi-
viduals (between-person effect) and how the individual differs
from their usual level (within-person effect).
Random intercepts and random slope were added to the empty
models if the model fit was improved. The data were modelled for
heteroscedastic residual variance over time, and quadratic time was
tested for improved model fit. Covariance structure like AR1 was
tested. The most parsimonious model was selected using log-
likelihood tests onmodel fit. A fixed linear timewith a heteroscedas-
tic residual variance over timewas chosen. AnAR1 covariance struc-
ture of the residuals gave the best model fit for anxiety and MCP1.
The covariance structure for TNF-α and IL-1RAwas homoscedastic.
TNF-α, IL-1RA, and MCP1 were modelled without random slope.
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Maximum likelihood (ML) was used as the estimation method
(Fitzmaurice et al., 2004).
First, we examined whether anxiety, metacognition, and cyto-
kines changed as a function of time and if anxiety and cytokines
correlated at pretreatment. Second, we investigated whether the
mean level of cytokine levels predicted the slope of anxiety.
Third, we examined whether the between- and within-person
effect of metacognitions predicted anxiety as was found in a recent
paper (Johnson et al., 2018). Finally, we investigated if the within-
person effect and between-person effect of metacognitions on
anxiety over the course of therapy wasmoderated by the mean level
of cytokines.
The mean level of cytokines was used since the cytokines did
not change over the course of therapy. We established a temporal
sequence between metacognitions and anxiety to ensure that the
predictor was measured before the outcome. The predictor scores
were lagged and thus related to the anxiety scores 4 days later. SPSS




The mean anxiety level at baseline was 28.7, SD = 13.4. Anxiety
level did not correlate with TNF-α, r= −0.09, p= 0.59, MCP1 lev-
els, r= 0.25, p= 0.15, or IL-1RA, r= 0.19, p= 0.26.
Change over time
First, we investigated whether the cytokines TNF-α, MCP1, IL-1RA,
and anxiety changed over the course of therapy. MCP1 [β= 2.77,
SE= 3.61, t(69.3)= 0.8, p= 0.44, CI (−4.4, 9.8)] did not change
significantly over the course of therapy, and the same was the
case for TNF-α [β = −0.09, SE= 0.20, t(66.6)= −0.5, p= 0.65,
CI (−0.49, 0.31)] and IL-1RA [β= 5.56, SE= 6.02, t(70.3)= 0.9,
p= 0.36, CI (−6.44, 17.56)]. However, anxiety decreased
[β = −1.19, SE= 0.19, t(35.6)= −6.09, p = <0.001, CI (−1.57,
−0.79)] significantly during therapy. Since the cytokines did not
change over the course of therapy, the mean level from the three
time points was used in the subsequent analysis.
Cytokines as predictor of outcome
We investigated whether the mean level of cytokines during treat-
ments predicted outcome. TNF-α, MCP1 or IL-1RA did not pre-
dict anxiety over the course of therapy (Table 1).
Within-person effects of metacognitions on anxiety
Table 2 shows that metacognitions predicted anxiety over the
course of therapy both on a within-person level and on a
between-person level.
Cytokines as predictors of within-person- and between-
person effects
The cytokines (MCP1, TNF-α, IL-1RA) did not moderate the
within-person effects or between-person effects of metacognitions
on anxiety (Table. 2). A higher level of metacognitions predicted a
higher level of anxiety through treatment (between-person effects),
but this relationship was not dependent on cytokines. A lower
metacognition in 1 week predicted a lower anxiety the next week
(within-person effect), but this relationship was also not dependent
on cytokines.
Discussion
Multiple cross-sectional studies have investigated the relationship
between immune markers and anxiety disorders; we tested the
hypothesis that mean levels of cytokines may predict the outcome
in comorbid anxiety disorders, and also whether the level of
cytokines moderated the relationship between a therapy process
(metacognitions) and anxiety. No such relationships were found,
although the results replicated the finding that metacognitive beliefs
predicted anxiety disorders as found in Johnson et al. (2018). Several
studies have used psychological construct to predict outcome in
psychotherapy, but this is the first study to investigate whether cyto-
kines affects the outcome for comorbid anxiety disorders.
The levels of circulating cytokines did not change significantly over
time, even though the anxiety symptoms subsided. One reason for the
lack of change might be that the sample consisted of comorbid and
previously treatment-resistant anxiety disorder patients. It might be
that these patients had a more chronically increased cytokine level
(e.g. Toft et al., 2018) due to the duration of their problems, hence
not displaying a trajectory related to treatment outcome.
Furthermore, some of the patients had PTSD, and it has previously
been shown that patients with PTSD increase their cytokine level dur-
ing treatment (Toft et al., 2018). The results from the current study of
treatment-resistant patients indicate that cytokine levels in patients
with anxiety disorders in general do not change over the course of
treatment, even if they report fewer symptoms.
Although TNF-α, MCP-1, and IL-1RA were unrelated to the
outcome in the present sample with anxiety disorder, there might
be subgroups of patients where cytokines are important. For exam-
ple, immune dysregulation is especially found in persons with a
late-onset anxiety disorder, suggesting the existence of a specific
late-onset anxiety subtype with a distinct aetiology (Vogelzangs
et al., 2013). This subgroup could not be analysed in the current
sample due to low sample size.
Metacognition predicted the outcome, both on a within-person
level and a between-person level. At the within-person level, a
decrease of a patient’s metacognitive beliefs in a given week was
associated with reduced anxiety in the subsequent week. At the
between-person level, the lower level of metacognitions predicted
lower overall level of anxiety. Thus, the importance ofmetacognition
as a key process in psychotherapy was corroborated (Wells, 2009;
Johnson et al., 2018). However, the level of cytokines did not mod-
erate this relationship.
Limitations
This study has several strengths. First, the sample consisted of
comorbid anxiety disorders, which is typical in clinical practice.
Moreover, cytokines were measured three times and anxiety and
metacognition weekly during treatment. Limitations regarding this
study should be acknowledged. We cannot rule out cytokine of
other classes that may have a bearing on metacognition and treat-
ment outcome. Even if the samples were taken at the same time of
the day and were handled swiftly in accordance with recommen-
dations (Altara et al., 2015; Aziz et al., 2016), we had little control
over the patients’ food intake (Zhou et al., 2010) and body mass
index. Due to sample size and power limitations, we could not
meaningfully separate between MCT and CBT in the analysis,
making possible interactions with treatment unknown.
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Some somatic diagnoses are likely to exert a chronic inflamma-
tory effect, for instance, hepatitis, cancer, HIV, or cardiovascular
disease, but unfortunately, we did not acquire any somatic diagnos-
tic information. Further, we did not run any tests for excluding
patients with ongoing somatic infection, for instance, C-reactive
protein analysis. Further, this study lacks a group of healthy con-
trols. Comparing cytokine levels between healthy controls and
patients could have provided interesting information about
differences between mentally ill and healthy people. However,
the aims of the study were met regardless of such limitations.
The lack of significance for cytokines as a predictor or moderator
may be due to a lack of power for testing moderation hypotheses, a
problem associated with many psychotherapy studies (Cuijpers
et al., 2016). However, as Arntz et al. (2015) argue, predictors could
be accumulated across different studies to build an empirical
knowledge base. In future research, a larger sample of patients with
anxiety disorders should be investigated, separating late or early
onsets of anxiety disorders. Furthermore, it should be investigated
whether the inflammatory levels depend on what kind of mecha-
nisms are targeted in therapy (Lasselin et al. 2016)
Conclusion
The clinical implication from this study is that variability in cyto-
kines is not related to the outcome in the treatment of anxiety
disorders.
Table 1. TNF-α, MCP1, and IL-1RA as predictors of anxiety among patients undergoing an inpatient treatment for treatment-resistant anxiety disorders
Variable TNF-α MCP1 IL-1RA
Fixed effects
Intercept 29.44*** (2.34), [24.7, 34.2] 26.28*** (2.89), [20.4, 32.2] 26.34*** (2.99), [20.2, 32.4]
Time −1.13*** (0.21), [−1.6, −0.71] −1.34 ***(0.27), [−1.89, −0.79] −1.14*** (0.28), [−1.7, −0.5]
TNF-α −0.16 (0.36), [−0.9, 0.6]
MCP1 0.08 (0.06), [−0.04, 0.21]
IL-1RA 0.06 (0.05), [−0.04, 0.16]
Time*TNF-α −0.02(0.04), [−0.09, 0.05]
Time*MCP1 0.004 (0.005), [−0.01, 0.01]
Time*IL-1RA −0.001 (0.004), [−0.01, 0.01]
Random effects
Intercept 139.1*** (41.9) 131.3*** (39.9) 132.9*** (40.5)
Covariance −0.27 (0.26) −0.32 (0.24) −0.26 (0.26)
Time 0.62 (0.33) 0.64* (0.32) 0.64 (0.33)
−2 LL 2460.82 2464.61 2468.18
*p < 0.05. ***p < 0.001. In brackets, 95% confidence intervals.
Table 2. Metacognitions as predictor of anxiety and MCPI, TNF-α, and IL-1RA as moderators of metacognitions on anxiety
Variable Metacognition MCP1 TNF-α IL-1RA
Fixed effects
Intercept −5.89 (4.9), [−15.9, 4.2] −15.1 (8.4), [−30.8, 2.0] −7.0 (6.0), [−19.2, 5.1] −10.46 (6.9), [−24.4, 3.5]
Time −0.75*** (1.9), [−1.1, −0.3] −0.8*** (0.2), [−1.2, −0.3] −0.8*** (0.2), [−1.2, −0.3] −0.74*** (0.2), [−1.2, −0.3]
Mcq_bp 0.51*** (0.07), [0.4, 0.7] 0.63***(0.11), [0.4, 0.9] 0.54***(0.09), [0.4, 0.7] 0.59*** (0.10), [0.4, 0.8]
Mcq_wp 0.25 ***(0.05), [0.16, 0.34] 0.25***(0.08), [0.10, 0.40] 0.26***(0.05), [0.15, 0.36] 0.30*** (0.08), [0.2, 0.5]
Cytokine 0.32 (0.24), [−0.16, 0.82] 0.54 (1.4), [−2.4, 3.4] 0.09 (0.12), [−0.15, 0.34]
Mcq_wp*cytokine −0.001 (0.001), [−0.003, 0.003] −0.003 (0.007), [−0.018, 0.012] −0.001 (0.001), [−0.004, 001]
Mcq_bp*cytokine −0.003 (0.002), [0.009, 0.002] −0.01 (0.03), [−0.06, 0.04] −0.002 (0.002), [−0.05, 0.01]
Random effects
Intercept 135.4*** (41.5) 134.9***(41.8) 142.1*** (44.2) 139.7***(43.9)
Covariance −0.84***(0.09) −0.84*** (0.1) −0.85*** (0.1) −0.85*** (0.3)
Time 0.62*(0.31) 0.61 (0.32) 0.62* (0.32) 0.64* (0.32)
−2 LL 2125.05 2148.41 2138.09 2150.23
MC, Metacognitions. In brackets, 95% confidence intervals; Mcq_bp, Metacognitions between-person effects; Mcq_wp, Metacognitions within-person effects.
*p < 0.05. ***p < 0.001.
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